Premium
The effect of the CYP2C19 * 2 heterozygote genotype on the pharmacokinetics of nelfinavir
Author(s) -
Burger David M.,
Schwietert H. Reinier,
Colbers E. P. H. Angela,
Becker Mark
Publication year - 2006
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2006.02635.x
Subject(s) - nelfinavir , cyp2c19 , pharmacokinetics , pharmacology , heterozygote advantage , genotype , allele , medicine , metabolite , population , biology , genetics , virology , gene , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom